Cytokine Market Report and Forecast 2025-2034

The global cytokine market size was valued at USD 92.67 Million in 2024, driven by the rising prevalence for personalised medicine across the globe. The market is expected to grow at a CAGR of 9.80% during the forecast period of 2025-2034, with the values likely to reach USD 236.03 Million by 2034.

Global Cytokine Market Overview

Cytokine refers to a group of small, short-lived proteins that are released by one cell to regulate the function of another cell, thereby serving as intercellular chemical messengers. Cytokine effect changes in cellular behavior that are important in several physiological processes, including reproduction, growth and development, and injury repair. Cytokines find their application across various therapeutic areas, particularly immunotherapy. Consequently, they are widely used in cancer and autoimmune disorder treatments. As per the data released by American Cancer Society, 2,001,140 new cancer cases and 611,720 cancer deaths are predicted to affect the United States population in 2024. Hence, the cytokine market demand is expected to witness an upswing in the coming years.

The market is driven by increasing application of cytokines in drug development and therapeutics along with rising investments from prominent companies to launch novel products and engage in research and development activities to strengthen their market position.

Increased Application in Cancer Therapeutics

Advancements in bioengineering have significantly helped in a better understanding of cytokine biology. The knowledge spans from receptor binding and cytokine structures, as a result, cytokine-based immunotherapy is becoming increasingly prevalent in recent years. In April 2023, Synthekine Inc., a United States based, engineered cytokine therapeutics company introduced a clinical trial design for orthogonal IL-2 and CD19 CAR-T combination therapy, STK-009 + SYNCAR-001. The increasing application of cytokines in cancer therapeutics is poised to enhance the cytokine market share in the forecast period.

Emphasis on Developing Effective Solutions to Address Multiple Indications

In December 2023, Equillium, Inc., announced an update on their multi-cytokine programs EQ101, and EQ102 to treat alopecia areata, celiac disease respectively. EQ101 was well tolerated in the 24-week dosing period in the Phase 2 study for alopecia areata. EQ102, a bi-specific inhibitor of IL-15 and IL-21, two cytokines central to T and B cell activity, is a potential candidate to treat skin and gastrointestinal diseases. Another promising candidate EQ302 (an orally delivered multi-cytokine inhibitor of IL-15 & IL-21) is also under investigation as it offers significant commercial and clinical benefits over EQ102. The increasing research and development activities in cytokines to address several diseases with efficiency and accuracy is poised to boost the cytokine market size during the forecast period.

Advent of New Technologies to Improve the Efficacy of Available Options

The healthcare and biotechnology industry has witnessed various technological advancements in recent years. Technical innovations have led to the emergence of various novel platforms to boost the effectiveness of options available and are anticipated to drive cytokine market growth in the upcoming years. In November 2023, Reverb Therapeutics launched a new Amplifier, an antibody-based platform for treating a broad range of diseases with endogenous cytokines that occur naturally within the body. Financed by Amplitude Ventures and Myeloma Investment Fund, the platform is designed to redirect a cytokine to a specific tumor, immune cell, or tissue, using elements of new and existing antibodies.

Global Cytokine Market Segmentation

“Cytokine Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:

Market Breakup by Cytokine Type

• Tumor Necrosis Factor-TNF
• Interleukins-II
• Interferons-IFN
• Epidermal Growth Factor-EGF
• Other Cytokine Types

Market Breakup by Application

• Cancer
• Asthma and Airway Inflammation
• Arthritis
• Other Therapeutic Applications

Market Breakup by Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Global Cytokine Market Regional Analysis

North America is expected to lead the market share for cytokines in the forecast period, which can be attributed to a robust research and development infrastructure in the region. The region is witnessing increased collaborations between key healthcare companies and academic institutions to develop effective and innovative solutions for chronic conditions including cancer, among others. Leveraging latest technologies, there is major focus on engineering T cells to carry cytokines IL-15 and IL-21 on their surface, which enhances their ability to kill cancer cells.

The Asia Pacific region is poised to witness substantial cytokine market growth in the forecast period. In January 2024, researchers from Osaka University discovered a new way to suppress the cytokine release storm (a condition where the body releases too many cytokines leading to inflammation) by blocking the IL-6 signals and minimizing the side effects. The ongoing research indicates that cytokines are a key area of research amongst scientists. In addition, the increasing technological advancements and infrastructure improvement is predicted to boost market growth in the region.

Global Cytokine Market: Competitor Landscape

In May 2023, CytoAgents, Inc., a clinical stage biotech company received FDA's go ahead to initiate Phase 1b/2a clinical trial for its Investigational New Drug (IND) CTO1681, o treat (cytokine release syndrome) CRS in lymphoma patients receiving CAR T-Cell Therapy. The new drug candidate targets the condition by regulating the body's natural response to sickness. With the new candidate, the company anticipates accelerating their clinical development efforts.

The key features of the cytokine market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• GSK PLC
• Novartis AG
• Amgen
• Pfizer Inc.
• Sanofi SA
• AstraZeneca plc
• Biocon Limited
• Abbvie Inc
• Johnson and Johnson
• UCB S.A.
• Thermo Fisher Scientific Inc.
• Novo Nordisk A/S
• Teva Pharmaceutical Industries Ltd.
• Sichuan Guoguang agrochemical co. ltd
• TCI Chemicals (India) Pvt. Ltd.

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

This product will be delivered within 3-5 business days.